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Abstract 
Purpose: To investigate the anti-proliferative, apoptotic and differentiating activities of Eurycoma 
longifolia root extracts on HL-60 leukemic cells.  
Methods: HL-60 cells were treated with different partially purified sub-fractions (F1 – F3) derived from 
the resin chromatography of the crude methanol root extract of E. longifolia roots, at different doses and 
time points. The anti-proliferative activity of E. longifolia was assessed via cell counting and trypan blue 
exclusion. Apoptosis was evaluated via Annexin-V FITC/IP and Hoechst staining. Flow cytometry and 
Wright staining were used to assess its differentiation activities. 
Results: F1 showed unremarkable growth inhibition rate while F2 and F3 showed growth inhibitory 
effects with median inhibitory concentration (IC50) values of 15.2 and 28.6 µg/ml, respectively. 
Treatment with F2 and F3 (100 µg/ml) for 96 h increased cell death from 3.3 to 95.5 and 76.3 %, 
respectively. Treatment with F2 (50 µg/ml) induced apoptosis by 14, 19.5 and 25 % after 24, 48 and 
72 h, respectively. No differentiation activity was observed, as indicated by absence of myeloid 
maturation and a non-significant CD14 positivity (p > 0.05). 
Conclusion: E. longifolia extract (F2) showed promising anti-leukemic activity and can be a candidate 
for the development of a drug for the treatment of acute promyelocytic leukemia (APL). 
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Acute promyelocytic leukemia (APL) is a distinct 
subtype of acute myeloid leukemia, accounting 
for approximately 10 – 15 % of all cases of this 
disease [1]. The treatment of APL with current 
chemotherapy is successfully achieved with a 
complete remission of 90 % [2].   Apoptosis is 
genetically regulated and morphologically 
characterized by cell shrinkage, the formation of 
apoptotic bodies, and DNA fragmentation in 
dying cells [3]. Methods employing the 
differentiation of leukemic blast cells have also 
been used as therapeutic approaches for the last 
three decades [4].  
 
The emergence of resistance to currently used 
drugs as well as high relapse rate create 
difficulties in the treatment of APL [5]. Therefore, 
studies on new compounds that can induce the 
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differentiation and/or apoptosis of APL cells are 
necessary. Medical herbs used in traditional 
medicine for cancer treatment are promising 
sources for such compounds.  
 
Eurycoma longifolia Jack (Tongkat Ali) is a 
slender, evergreen flowering tree from the 
Simaroubaceae family present in Southeast Asia 
[6]. The plant is rich in various bioactive 
compounds, such as eurycomanole [7], 
eurycomanone, eurycomalactone, 13α (21)-
epoxyeurycomanone, 9-methoxycanthin-6-one, 
canthin-one alkaloids, β-carboline alkaloids, 
squalene derivatives, biphenylneolignans, 14,15 
β-dihydroxyklaineanone and tirucallane-type 
triterpenes [8]. The anti-cancer activities of E. 
longifolia on various solid tumors, including lung 
[9], breast [10] and cervical cancers [11] have 
been reported. However, studies on the 
antileukemic activity of this plant have not been 
conducted. Accordingly, the present study aims 
to investigate, the anti-proliferative, apoptotic, 
and differentiation activities of E. longifolia on the 






The plant and root samples of E. longifolia Jack 
were identified by Professor Ahmad Latif from 
Universiti Kebangsaan Malaysia (UKM). The 
plant samples were collected in 2003 from Perak, 
Malaysia. A voucher specimen (no. 785-117) 
was deposited in the herbarium of Penang 
Botanical Garden, Penang, Malaysia. 
 
The F1, F2 and F3 were partially purified sub-
fractions derived from resin chromatography of 
the crude methanol extract of E. longifolia roots 
as previously reported [12]. Briefly, powdered 
roots of E. longifolia Jack were extracted with 95 
% methanol at 60 °C for 6 hours per day. It was 
filtered and the residue further extracted 
consecutively with two fresh portions of solvent 
for 5 days. The combined filtrate was then 
concentrated to dryness under partial vacuum at 
room temperature of 24 - 27 °C to yield a dark 
brown residue. The combined extract was next 
fractionated by column chromatography, using 
Diaion HP 20 column with a H2O–MeOH (1:0–
0:1) gradient, to yield 4 fractions of the desired 
quassinoid-rich E. longifolia extract. Before the 
treatment, stock solutions, 5 ml each, of F1, F2 
and F3 were prepared at a concentration of 10 
mg/ml. F1 was dissolved in dimethyl sulfoxide 
(DMSO) while F2 and F3 were dissolved in 
water. All the fractions were sterilized by filtration 
using a syringe filter (0.2 µm, Sartorius, 
Germany). 
Cells and culture medium 
 
The human promyelocytic leukemia cell line HL-
60 was obtained from American Type Culture 
Collection (ATCC). Cells were maintained in 
RPMI 1640 medium (Sigma) containing 10 % 
fetal bovine serum (Sigma), 2 mM L-glutamine, 
and 100 U/ml penicillin and streptomycin 
(Hyclon). The cells were cultured at 37 °C in a 
humidified incubator containing 5 % CO2. RPMI 
1640 medium was used in all experiments. 
 
Assessment of anti-proliferation 
 
HL-60 cells (3 × 105/ml) were suspended in 2 ml 
culture medium in 24-wells cell culture plates and 
treated with F1 , F2 and F3 at various 
concentrations (6.25 – 100 µg/ml) and time 
points (0 – 96 h). HL-60 cells also were treated 
with vincristine (positive control) at the 
concentrations of 0.0625, 0.125, 0.25, 0.5 and 
1µg/ml at the same time points. Untreated cells 
acted as a negative control. At each time point, 
the cell suspensions were mixed at a ratio of 1:1 
with 0.4 % trypan blue solution (Sigma) and 
incubated for 3 - 5 min. The viable cells were 
counted using a hemocytometer chamber. Cell 
growth inhibition (CGI, %) at each concentration 
was calculated according to Eq 1.  
 
CGI (%) = (1 – Ct/Cu)100 ………………….. (1) 
 
where Ct is the viable count of treated cells and 
Cu the viable count of untreated cells. Inhibitory 
concentration (IC50) values were calculated by 
plotting growth inhibition rate versus 
concentration. Trend line was drawn and a 
suitable calibration curve with correlation 
coefficient (r2) > 0.95 was determined and 
applied appropriately. The results are reported as 




HL-60 cells (3 × 105/ml) were treated with F2 and 
F3 for 24, 48, 72 and 96 h at concentrations of 
25, 50 and 100 µg/ml. The treated and untreated 
cells were examined and photographed under an 
inverted microscope (IX51 Olympus). For the 
assessment of chromatin condensation, slide 
smears of the treated and untreated HL-60 cells 
at the indicated time points were prepared, air-
dried, fixed with absolute methanol, and stained 
with 10 µg/ml Hoechst 33258 dye for 20 min at 
37 °C in the dark. The incubated slides were 
washed with phosphate-buffered saline (PBS), 
allowed to dry in a dark chamber, and then 
examined under a fluorescence microscope 
(Olympus BX51). 
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Measurement of apoptosis via flow cytometry  
 
The HL-60 cells were exposed to F2 at various 
concentrations and time points (24, 48, and 72 
h). After each time point, the cells were 
harvested, washed, and re-suspended at 1 × 105 
in cold PBS. Apoptotic cells were identified using 
Annexin V/PI Apoptosis Detection kit (BD 
Pharmingen™) according to the manufacturer's 
instructions. Flow cytometric analysis was 
performed within 1 h of staining. The number of 
early apoptotic and late apoptotic/necrotic cells 
were determined as the percentage of Annexin 
V+/PI− and Annexin V+/PI+, respectively. Data 
acquisition and analysis were performed using a 
Becton Dickinson flow cytometer with CellQuest 
software.  
 
Assessment of differentiation 
 
HL-60 cells (2 × 105/ml) were treated with F2 (20, 
50 and 100 µg/ml) for up to 7 days (24 h interval) 
to determine the maturation process. Untreated 
HL-60 cells were also maintained in culture 
medium at the same time intervals. The treated 
and untreated cells were then harvested via 
centrifugation and washed three times in PBS. 
The HL-60 cells were smeared onto glass slides, 
air-dried, stained with Wright stain, and 
examined under a light microscope. 
Differentiation was also assayed with regard to 
the HL-60 cells, treated for 7 days at various 
concentrations of F2, via flowcytometric analysis 
of CD14 expression. As previously reported [13], 
treated and untreated HL-60 cells were 
incubated with anti-CD14 antibody (BD 
Biosciences) for 30 minutes at 4 0C followed by 
washing (twice) with cold PBS. Flow cytometric 
analysis was performed on them within 1 h. 
 
Statistical analysis  
 
The results are presented as mean ± SD and 
differences between groups were compared by 
Student’s t-test using SSPS, version 11.5. Data 






F2 and F3 inhibited cell growth in a time- and 
dose-dependent manner (Figure 1). Mean IC50 
values for F2 and F3 were 15.2 and 28.6, µg/ml, 
respectively. Vincristine strongly inhibited the 
growth of HL-60 cell with IC50 of 0.3 µg/ml. HL-60 
cells treated with F1 showed a similar growth 
rate to the untreated cells at all concentrations 
used. Based on the anti-proliferative findings, F2 




Figure 1:  Effect of E. longifolia extracts (F1- F3) on 
HL-60 cell growth rate (GR). HL-60 cells treated with 
various concentrations of F1, F2 & F3 for 96 h. Results 
are expressed as mean ± SD, (n = 3). (○ = F1; □ = F2; 
● = F3). 
 
Death (%) was also dose- and time-dependent. 




Nuclear condensation was dose and time-
dependent and clearly noted in the HL-60 cells 
treated with F2 (100 µg/ml) after 48 - 72h (Figure 
2). Shrinkage and fragmentation of the treated 
cells were also observed during examination of 
treated cells in the cell culture plates. 
Photographs of treated and untreated cells, 
taken at the indicated time points, showed that 
morphological changes were time and dose-
dependent. Figure 3 shows the morphologically 
changed HL-60 cells after 48 h of treatment with 
F2 (100 µg/ml). Early changes (3 h) were 
observed in the cells treated with more than 400 
µg/ml of F2 (data not shown). 
 
Table 1:  Death of the HL-60 cells treated with various fractions of F2 and F3 at zero time and 96 h 
 
F2 (µg/ml) F3 (µg/ml)  
6.2 12.5 25.0 50.0 100.0 6.2 12.5 25.0 50.0 100.0 
Control 
Death (%) *at 0 h 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 3.3 
Death (%) at 96 h 8.0 17.0 30.0 73.3 95.5 
 
8.4 10.9 20.9 31.2 76.3 8.5 
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Figure 2:  Apoptotic nuclear changes in (A) non-
treated (control) and (B) F2-treated (100 µg/ml ) HL-60 
cells after 72 h cultivation. HL-60 cells stained with 
Hoechst 33258 (10 µg/ml) were observed under a 
fluorescence microscope (×40) 
 
 
Figure 3:  Morphology of (A) untreated and (B) F2-
treated (100 µg/ml) HL6 cells after 48 h cultivation. 
The cells were observed under an inverted 




Wright stain of HL-60 cells incubated with and 
without F2 at different time points showed that 
the cells remained in the blast stage despite the 
morphologic changes (nuclear condensation and 
membrane blebbing) observed in a number of 
the treated cells; that is, none of the cells 
differentiated into mature cells (Figure 4). CD14 
expression on the treated HL-60 cells was not 
statistically significant, compared with the 
untreated cells (p > 0.05)  
 
         
 
Figure 4:  Morphologic changes in (A) untreated 
(control) and (B) F2-treated HL-60 cells after 48 h 
cultivation. The cells were harvested, washed with 
PBS, stained with Wright stain, and then examined 




Treatment with the extract resulted in induction of 
apoptosis in a time- and dose-dependent 
manner. Treatment of the HL-60 cells with F2 (50 
µg/ml) increased early apoptotic cells from 14 % 
after 24 h to 19.5 and 25 % after 48 and 72 h, 
respectively while 100 µg/ml increased early 
apoptotic cells to 20 % after 24 h (p < 0.05). 
 
DISCUSSION   
 
The main characteristic feature of APL is that 
immature cells are blocked at an early stage of 
development and they fail to differentiate into 
functional cells [14]. Therapeutic strategies 
based on induction of differentiation and 
apoptosis is currently the standard method for 
APL treatment [4]. Although terminal 
differentiation and complete remission has been 
achieved in a majority of APL patients treated 
with all-trans retinoic acid (ATRA) [15], the 
inability to eliminate leukemic cells and the 
emergence of resistance [16] have led to 
combining this drug with other drugs (e.g., 
arsenic).  
 
The results of the present study clearly show that 
E. longifolia has a potential anti-leukemic activity, 
as indicated by IC50 values 15.2 and 28.6 µg/ml 
for F2 and F3, respectively, as well as increased 
death rates. The difference in sensitivities of the 
two fractions might be due to their different 
chemical constituents and/or variation in the 
concentration(s) of the active compound(s). 
Eurycomanone is the major constituent of F2 and 
represent about 20 w/w% [6, 17]. Other 
compounds isolated from this fraction include 
13,21-dihydroeurycomanone, 13α(21)-
epoxyeurycomanone and 2,3-Dehydro-4a-
hydroxylongilactone with lower concentrations 
[6,12]. The cytotoxcity (IC50 of 45 ± 0.15 µg/ml) of 
E. longifolia crude extract towards HepG2 cells 
has been reported [18]. Eurycomanone showed 
potential cytotoxic effect on CaOv-3, HeLa, 
HepG2, HM3KO and MCF-7 cancer cells with 
IC50 around 5 – 10 µM [11].   F2 induced cell 
membrane changes and caused 
phosphatidylserine externalization, as indicated 
by Annexin V positivity. Nuclear changes 
(chromatin condensation) were also dose- and 
time-dependent. These findings suggest 
induction of apoptosis which is a therapeutic 
target for many chemotherapeutic agents. In a 
previous study, Nurkhasanah and Azimahto [11] 
found that eurycomanone induced apoptosis in 
cervical cancer Hela cells with up regulation of 
p53 and Bax and down regulation of Bcl-2 genes. 
Induction of apoptosis in MCF-7 breast cancer 
cell with methanol E. longifolia root extract was 
also reported by Tee et al [9]. 
 
The absence of cell maturation and CD14 
positivity in the HL60 cells after treatment with F2 
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indicates that this plant has not differentiation 
activities on this cell line. 
 
The findings of this study showed that the E. 
longifolia root extracts caused the cytotoxic effect 
via the apoptotic mechanism and this effect is 




E. longifolia root extract (F2) has a potential anti-
proliferation activity on HL60 cells, which occurs 
through the induction of apoptosis rather than 
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